NEW YORK (GenomeWeb News) – Trovagene today said that it has entered into a memorandum of understanding with Strand Life Sciences, under which Strand will license and validate Trovagene's human papillomavirus urine test and high-risk HPV DNA assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.